Skip to main content
. 2008 Mar 11;111(12):5515–5523. doi: 10.1182/blood-2007-10-117150

Table 3.

Frequencies and odds ratios of chronic medical conditions and adverse health status in siblings, all ALL survivors, and nonrelapsed, nonirradiated survivors (restricted to those age 18 years and older)

Outcome Siblings, n (%) All ALL survivors, n (%) OR for all ALL survivors vs siblings (95% CI) P Nonrelapsed, nonirradiated survivors, n (%) OR for nonrelapsed, nonirradiated survivors vs siblings (95% CI) P
Number in each group 3083 2599 426
Chronic medical conditions
    Hearing 12 (0.4) 27 (1.0) 3.0 (1.5-6.8) <.001 4 (0.9) 2.7 (0.5-7.8) .17
    Vision 21 (0.7) 30 (1.2) 1.6 (0.9-3.1) .19 2 (0.5) 0.5 (0.1-1.6) .26
    Endocrine 56 (1.8) 114 (4.4) 3.1 (2.3-4.5) <.001 5 (1.2) 1.0 (0.2-2.2) .96
    Pulmonary 37 (1.2) 78 (3.0) 4.2 (2.8-6.6) <.001 8 (1.9) 2.7 (1.0-5.1) .05
    Cardiac 21 (0.7) 82 (3.2) 6.9 (4.212.9) <.001 6 (1.4) 3.8 (0.9-10.0) .06
    Gastrointestinal 14 (0.5) 18 (0.7) 2.2 (1.0-5.0) .04 1 (0.2) 1.0 (0.2-5.7) .96
    Renal 5 (0.2) 21 (0.8) 4.8 (2.118.9) <.001 2 (0.5) 4.1 (0.5-37.0) .29
    Musculoskeletal 3 (0.1) 14 (0.5) 7.7 (2.821.3) <.001 4 (0.9) 22.8 (4.0-128.1) .03
    Neurologic 13 (0.4) 62 (2.4) 5.3 (3.111.4) <.001 3 (0.7) 1.6 (0.5-5.4) .49
    Grade 3 to 4 179 (5.8) 382 (14.7) 3.7 (3.0-4.5) <.001 34 (8.0) 2.0 (1.3-3.0) .01
    2 or more in grades 1 to 4 433 (14.0) 667 (25.7) 2.8 (2.4-3.2) <.001 73 (17.1) 1.9 (1.4-2.5) <.001
Adverse health status
    General health 157 (5.1) 230 (8.9) 2.1 (1.6-2.7) <.001 24 (5.6) 1.2 (0.7-1.9) .45
    Mental health 302 (9.8) 389 (15.0) 1.7 (1.4-2.0) <.001 61 (14.3) 1.6 (1.1-2.1) .01
    Activity limitation 178 (5.8) 230 (8.9) 1.8 (1.5-2.3) <.001 28 (6.6) 1.3 (0.8-2.0) .25
    Functional impairment 79 (2.6) 227 (8.7) 4.1 (3.1-5.6) <.001 18 (4.2) 2.0 (1.0-3.3) .05

CI indicates confidence interval.

* Adjusted for age at interview, sex, and ethnicity.

Adjusted for cumulative anthracycline dose, alkylator score, age at interview, age at diagnosis, sex, and ethnicity.